kures srl

What kures srl does

Kures S.r.l. is an Italian medical device company founded in 2019 as a spin-off from Kardia, headquartered in Pero (Milan). It develops the KING (Kidney Instant Monitoring) system, a biomedical monitoring platform that connects to patients via a urethral catheter to deliver continuous, real-time measurement of urinary parameters — pH, sodium, potassium, chloride, ammonium ion (NH4+), and diuresis — for use in intensive care units and operating rooms. KING is positioned as the only commercially available system capable of directly monitoring ammonium ion concentration in urine, and it produces calculated clinical indicators such as Strong Ion Difference (SID), excretion rate, and urine flow to support hemodynamic and electrolyte management decisions in critically ill and perioperative patients. The product holds ISO 13485:2016 certification and has been recognized by the European Commission Horizon program.

Kures monetizes through a combined hardware-and-consumables model: hospital customers purchase the KING device and then procure recurring consumables, including the K-DB-0100 Urine Sampler Kit, branded ion-selective electrodes (pH, Chloride, Potassium, Ammonium, Sodium, Reference), a Dummy Cell, and the K-DB-0041 Reagent Pack. Go-to-market is enterprise direct sales to hospital ICUs and ORs in Italy, supplemented by KOL-led clinical education through webinars (featuring intensivists such as Professor Pietro Caironi and Professor S. Romagnoli), in-hospital workshops, and sponsorship of Italian and European anesthesia and critical care congresses (SMART, AIIC, SIAARTI, ITACTAIC, and the Nice Applied Physiology Symposium). KING was a finalist at the 2024 AIIC awards for innovation in diagnostics and healthcare technology, and commercial hospital installations began in 2024.

Name

kures srl

Legal name

Kures S.r.l.

Website

https://kures.it

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Kures S.r.l. is an Italian medical device company that develops the KING (Kidney Instant Monitoring) system, a real-time renal monitoring platform for hospital intensive care units and operating rooms, selling hardware paired with proprietary consumables to clinical customers in Italy and select European markets.

Ownership category

akta.pro rank

Product category

Medical Device Monitoring

NAICS

Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status) (HLAHAKAJ)

akta.pro secondary industry

Urinalysis & Kidney Function POCT (Dipstick, Microalbumin, Creatinine) (HLAHAOAE)

Keywords

• Renal monitoring systems
• Critical care medical devices
• Biomedical monitoring equipment
• Operating room monitoring
• Urinary electrolyte analysis

Headquarters

HQ city

Pero (Milan)

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Others

Revenue model

1. KING Hardware System Sales: Sale of the KING monitoring device hardware to hospitals and healthcare facilities for use in ICUs and operating rooms
2. Consumables Revenue: Recurring revenue from consumables including Urine Sampler Kit, specialized electrodes, and Reagent Packs that require regular replacement for continuous patient monitoring

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Kures develops and sells the KING (Kidney Instant Monitoring) system, a real-time biomedical monitoring device that connects to critically ill and surgical patients via urethral catheter to continuously measure renal parameters including urine pH, sodium, potassium, chloride, ammonium ion concentrations, and diuresis. The company complements the KING hardware with a proprietary suite of consumables—urine sampler kits, specialized electrodes, and reagent packs—sold to hospital intensive care units and operating rooms for use in critical care and major surgery monitoring.

Product overview

Kures Srl offers a unified medical device ecosystem centered on the KING (Kidney Instant Monitoring) system for real-time renal monitoring in intensive care and operating room settings. The product portfolio consists of the core KING monitoring device complemented by a comprehensive range of consumables including urine sampler kits, specialized electrodes (pH, chloride, potassium, ammonium, sodium, and reference electrodes), dummy cells, and reagent packs. All consumables are specifically engineered for compatibility with the KING system to ensure optimal performance and reliability in critical care environments.

Differentiator

Problem solved

Functional benefit

Brands

• KING (Kidney Instant Monitoring): Advanced real-time renal monitoring system for critical care and operating room settings, providing precise measurements of urinary pH, sodium, potassium, chloride, ammonium concentrations, and diuresis.

Products and services

• KING (Kidney Instant Monitoring) System Advanced real-time renal monitoring system that connects to patients via urethral catheter, providing precise measurements of urine pH, sodium, potassium, chloride, ammonium concentrations, and diuresis for critical care and operating room monitoring. Designed for intensivists and anesthesiologists managing critically ill and surgical patients.
• K-DB-0100 Urine Sampler Kit Fluidic device that transfers urine from the catheter/patient to the KING analytical device and the urine collection bag. Used in hospitals with the KING monitoring system.
• K-DB-0017 Electrode pH pH electrode for the analytical device component of the KING system.
• K-DB-0018 Electrode Chloride Chloride electrode for the analytical device component of the KING system.
• K-DB-0019 Electrode Potassium Potassium electrode for the analytical device component of the KING system.
• K-DB-0020 Electrode Ammonium Ammonium electrode for the analytical device component of the KING system.
• K-DB-0021 Electrode Sodium Sodium electrode for the analytical device component of the KING system.
• K-BM-0005 Electrode Reference Reference electrode for the analytical device component of the KING system.
• K-DB-0022 Dummy Cell Dummy cell component for the KING analytical device.
• K-DB-0041 Reagent Pack Compact design reagents and waste pack for the KING system.

Quantifiable outcome

• Electrolyte concentrations can fluctuate up to 50-100 times within minutes - KING provides immediate insights for timely interventions
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• KardiacoreStrategic or Co-development Partner · 1 January 2019Kures was founded in 2019 as a spin-off from Kardia, led by two visionary entrepreneurs and internationally renowned intensive care clinicians. The founders combined their scientific insights and expertise to develop the KING monitoring system for critical care applications.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/kures-srl

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about kures srl